Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2008-07-15
2008-07-15
Helms, Larry (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C530S387300, C536S023530
Reexamination Certificate
active
07399594
ABSTRACT:
Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and nonhuman CDRs.
REFERENCES:
patent: 4470925 (1984-09-01), Auditore-Hargreaves
patent: 5530101 (1996-06-01), Queen et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5908925 (1999-06-01), Cohen et al.
patent: 6254868 (2001-07-01), Leung et al.
patent: 2002/0177170 (2002-11-01), Luo et al.
patent: 2003/0040606 (2003-02-01), Leung
patent: 2003/0109680 (2003-06-01), Wong et al.
patent: 2003/0190705 (2003-10-01), Wong et al.
patent: 0939127 (1999-09-01), None
patent: WO03/002607 (2003-01-01), None
patent: WO03/025019 (2003-03-01), None
Rudikoff et al (Proc. Natl. Acad. Sci. USA 79:1979 (1982)).
Rosok et al. (J. Biol. Chem. 271(37):22611-22618 (1996)).
Harris et al., Prot. Sci. 4:306-310 (1995).
Takeda S.: Nature. Apr. 4-10, 1985;314 (6010):452-4; Construction of Chimaeric Processed Immunoglobulin Genes Containin Mouse Variable and Human Constant Region Sequence.
Jones PT. Nature. May 29-Jun. 4, 1986;321 (6069);522-5 Replacing the Complementaryity-Determining Regions in a Human Antibody With Those From a Mouse.
Sato K. Mol Immunol. Apr. 1994;31 (5):371-81. Humanization of a Mouse Anti-Human Interleukin-6 Receptor Antibody Comparing Two Methods For Selecting Human Framework Regions.
Chothia C.: J Mol Biol. Aug. 1987;196(4):901-17. Canonical Structures For the Hypervariable Regions of Immunoglobulins.
Foote J: J Mol Biol. Mar. 20, 1992;224 (2): 487-99. Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops.
Santos AD, Prog Nucleic Acid Res Mol Biol. 1998; 60:169-94; Development of More Efficacious Antibody for Medical Therapy and Diagnosis.
Rosok MJ, J Biol Chem. Sep. 13, 1996;271 (37):22611-8 A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab.
Reichmann L. et al., Nature 332, 323-327,1988. Reshaping Human Antibodies for Therapy.
Yelton et al. Affinity Maturation Of The BR96 Anti-Carcinoma Antibody By Codon-Based Mutagenesis. The Journal Of Immunology. 1995, pp. 1994-2004.
Vol. 272, No. 16, Issue of April 18, 1997 pp. 10678-10684. Antibody Humanization Using Monovalent Phage Display.
PCT Search Report.
“Humanization of Immu31, an α-Fetoprotein-specific Antibody”, Qu et al.,Clinical Cancer Research, The American Association For Cancer Research, US, vol. 5, No. 10, pp. 3095S-3100S (1999).
“Construction and Characterization of Humanized, Internalizing, B-Cell (CD22)-Specific, Leukemina/Lymphoma Antibody, LL2”, Leung et al.,Molecular Immunology, vol. 31, pp. 17-18 (1995).
Baca, M. et al., “Antibody Humanization Using Monovalent Phage Display,”J. Biol. Chem.272(16): 10678-10684, (1997).
Benhar, I. et al., “Rapid humanization of the Fv of monoclonal antibody B3 by using framework enchange of the recombinant immunotoxin B3(Fv)-PE38,”Proc. Natl. Acad. Sci. USA 91: 12051-12055, (Dec. 1994).
Couto, J. et al., “Anti-BA46 Monoclonal Antibody Mc3: Humanization Using a Novel Positional Consensus and in Vivo and in Vitro Characterization,”Cancer Res. 55:1717-1722, (Apr. 15, 1995).
Leung, S-O. et al., “Construction and Characterization of a Humanized, Internalizing, B-Cell (CD22)-Specific Leukemia/Lymphoma Antibody, LL2,”Mol. Immunol. 32(17/18): 1413-1427, (1995).
Radar, C. et al. “A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries,”Proc. Natl. Acad. Sci. USA 95: 8910-8915, (Jul. 1998).
Ohtomo, T. et al. “Humanization of Mouse ONS-M21 Antibody with the aid of hybrid variable regions,”Mol. Immunol. 32(6): 407-416, (1995).
Rother Russell P.
Wu Dayang
Alexion Pharmaceuticals, Inc.
Bristol Lynn
Helms Larry
Ropes & Gray LLP
LandOfFree
Hybrid antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hybrid antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hybrid antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2792403